OraSure Technologies (OSUR) Stock Rating Lowered by BidaskClub

OraSure Technologies (NASDAQ:OSUR) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

Several other equities analysts have also recently weighed in on OSUR. Zacks Investment Research cut OraSure Technologies from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 7th. ValuEngine raised OraSure Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, November 6th. TheStreet cut OraSure Technologies from a “b” rating to a “c+” rating in a report on Thursday, November 8th. Finally, Raymond James reissued a “mkt perform” rating on shares of OraSure Technologies in a report on Tuesday, October 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $20.50.

Shares of OSUR opened at $12.63 on Wednesday. OraSure Technologies has a 12 month low of $12.27 and a 12 month high of $22.22. The firm has a market cap of $774.19 million, a price-to-earnings ratio of 24.76, a price-to-earnings-growth ratio of 3.13 and a beta of 1.54.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, November 7th. The medical instruments supplier reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The firm had revenue of $45.90 million for the quarter, compared to analysts’ expectations of $44.50 million. OraSure Technologies had a return on equity of 6.58% and a net margin of 9.49%. The company’s revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.09 EPS. As a group, equities research analysts anticipate that OraSure Technologies will post 0.32 earnings per share for the current year.

A number of large investors have recently bought and sold shares of OSUR. Morgan Stanley raised its holdings in OraSure Technologies by 352.3% during the third quarter. Morgan Stanley now owns 1,290,002 shares of the medical instruments supplier’s stock valued at $19,930,000 after acquiring an additional 1,004,774 shares during the period. BlackRock Inc. grew its position in shares of OraSure Technologies by 10.6% during the second quarter. BlackRock Inc. now owns 8,480,830 shares of the medical instruments supplier’s stock valued at $139,679,000 after purchasing an additional 810,442 shares in the last quarter. Penn Capital Management Co. Inc. grew its position in shares of OraSure Technologies by 583.7% during the third quarter. Penn Capital Management Co. Inc. now owns 710,653 shares of the medical instruments supplier’s stock valued at $11,899,000 after purchasing an additional 606,709 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of OraSure Technologies during the third quarter valued at about $8,489,000. Finally, Systematic Financial Management LP grew its position in OraSure Technologies by 520.8% in the third quarter. Systematic Financial Management LP now owns 499,254 shares of the medical instruments supplier’s stock worth $7,713,000 after acquiring an additional 418,833 shares in the last quarter. 92.63% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

See Also: Stock Symbols Definition, Examples, Lookup

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply